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Intravenous nitrates are widely used in the management of acute heart failure syndrome 
(AHFS), yet with lack of robust evidence to support their use. We therefore sought to 
analyse all randomised studies that evaluated the effects of nitrates on clinical outcomes in 
patients with AHFS. In total, fifteen relevant trials comparing nitrates and alternative 
interventions in 1824 patients were identified. All but three were conducted before 1998. 
No trials demonstrated a beneficial effect on mortality, apart from one trial reporting a 
reduction in mortality, which was related to the time of treatment. Retrospective review 
suggests that there is a lack of data to draw any firm conclusions concerning the use of 
nitrates in patients with AHFS. More studies are needed to evaluate the safety and efficacy 
of these agents in the modern era of guideline-directed use of heart failure therapy. 
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AHFS: acute heart failure syndrome 
IHD: ischaemic heart disease 
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Heart failure is a chronic, progressive clinical syndrome that results from any structural or 
functional impairment of ventricular filling or ejection of blood causing symptoms and signs 
of pulmonary congestion . Acute heart failure syndrome (AHFS) is defined as the sudden 
change or the rapid deterioration of symptoms and signs of heart failure, often in response 
to certain precipitating factors (for example, myocardial ischaemia, cardiac arrhythmia, 
septicaemia and non-compliance with either drug, or diet therapy, or both), which require 
urgent medical attention . Over the last 25 years, despite advances in heart failure diagnosis 
and management, it remains a common yet complex syndrome associated with high rates of 
morbidity and mortality. Heart failure continues to represent a major and growing burden 
on public health worldwide, both in terms of its prevalence and poor prognosis. This is, at 
least in part, because the contemporary medications that are received by heart failure 
patients are often insufficient to fully prevent hospitalisations (1). Also, there has been little 
research into the management of acute heart failure syndrome (AHFS), with many 
treatment strategies being based on clinical experience, rather than on evidence from high 
quality studies. Nitrates are widely used in patients with heart failure, yet evidence 
supporting their use is apparently scarce.  
Historical drug treatments for heart failure syndromes included only diuretics and digitalis, 
mainly for the relief of symptoms of congestion rather than for a mortality benefit or 
morbidity reduction (2). This prompted further search for other agents as potential 
treatments, especially in patients with advanced heart failure. In the early 1970s, initial 
vasodilator studies in heart failure showed some added haemodynamic benefits with the 
use of nitrates, mainly through reduction of preload (3, 4). Observational studies suggested 
that the addition of the nitric oxide donor isosorbide dinitrate (ISDN) in acute 
decompensated heart failure (ADHF) was associated with lower all-cause mortality and 
favourable long-term clinical outcomes, but without reduction in rehospitalisation rate (5, 
6). Interest in nitrate therapy has increased further as a result of the widespread use of 
intravenous nitrates in the emergency management of AHFS.  
Standard guideline-directed therapy for heart failure has changed dramatically over the last 
25 years (7). The beneficial effects of nitrates may or may not have been masked by newer 
heart failure treatments. Moreover, it is unclear whether nitrates can significantly improve 
symptoms of heart failure, although it is widely believed that they do. It is also uncertain 
whether the effect of these agents confers a different effect on different heart failure 
phenotypes (for example, heart failure with preserved systolic function, heart failure with 
reduced systolic function, ischaemic heart disease, valve disease, etc). Previous reviews that 
studied nitrates in acute heart failure have been small, and included only a few studies (8, 
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9). Perhaps this is due, in part, to the fact that most prior studies are considered dated, with 
inaccurate methodology, which might have shaped final results. Recently, a study of home 
monitoring using a pulmonary artery pressure monitoring device demonstrated a 
substantial reduction in rehospitalisation rate, but not mortality, in patients with 
symptomatic heart failure (10). Apart from diuretics, nitrates were the main agents used to 
reduce pulmonary pressure, which appeared to be the main mechanism by which the 
benefit was achieved. In order to examine the evidence for use of nitrates in heart failure, 
we sought to analyse studies that evaluated the effects of nitrates on clinical outcomes. 
 
METHODS 
The study was designed according to the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analyses) Statement (11). Inclusion criteria were as follows: randomised 
controlled trials assessing nitrates, versus placebo, or no therapy, or an active comparator, 
whether parallel or multiple arms (i.e. other arms with different class, route and dosage). 
Participants were patients who received nitrates for the management of ADHF. 
Observational studies, registries and studies conducted in chronic heart failure, were 
excluded.  
The PubMed/Medline, Embase, Scopus and Cochrane Central Register of Controlled Trials 
databases were searched up to August 2015. All studies assessing the effects of nitrates in 
acute heart failure, and reporting the effect on clinical endpoints were included, with no 
language restrictions. Eligible studies were identified with the following headings: nitrates, 
nitroglycerine, nicorandil, isosorbide mononitrate, isosorbide dinitrate, glyceryltrinitrate, 
sodium nitroprusside, heart failure, cardiac failure, ventricular failure, randomly, random 
and randomised controlled trial. Reference lists of the retrieved articles were searched to 
identify other eligible studies. Furthermore, online oral presentations and expert slide 
presentations were examined.   
The study investigators independently reviewed all titles, or titles and abstracts from the 
search results to identify articles according to the fulfilment of inclusion criteria. Selected 
trials were compared, and discrepancies were resolved by team discussion. Data extraction 
was carried out independently and in duplicate by the study investigators. Results of data 
extraction were then compared, and any discrepancies were resolved by team discussion. If 
results were incomplete or unclear, the study authors were contacted. Articles finally 
selected for the review were checked to avoid inclusion of data published in duplicate. 
Relevant data was collected on baseline patient characteristics, heart failure phenotype, 
presence of ischaemic heart disease, New York Heart Association (NYHA) functional 
classification, background heart failure therapy, study interventions, and clinical outcomes 
at baseline and end of follow-up. 
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Of 4,415 articles identified by the initial search, 75 were retrieved for more detailed 
evaluation [Figure 1]. 33 studies were excluded from the review, because they assessed the 
effects in chronic heart failure [Supplementary Appendix 1-33]. 27 studies primarily 
addressed tolerance issues (e.g. clinical pharmacological trials) [Supplementary Appendix 34-
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Mechanism of action  
 
Many nitrates (e.g. nitroglycerine, isosorbide mononitrate and isosorbide dinitrate) exert 
their effects in the human body by being converted to nitric oxide (NO). NO is recognized as 
the most important cellular signalling molecule involved in many physiological and 
pathological cardiovascular processes (12). There has been a growing body of evidence to 
suggest that NO production, as a potent natural vasodilator and a major biological regulator 
of cardiovascular function, is impaired in patients with heart failure, thus indicating a 
potential significant beneficial effect of NO enhancing therapy with nitrates (13, 14).  
 
Evidence for use in AHFS 
 
Fifteen randomised studies including a total of 1824 AHFS patients and reporting clinical 
outcomes were identified. Two small studies including 35 patients with a mean age of 51±8 
years studied the combination therapy of nitrates and hydralazine. Of these, one study 
compared the combination to either drug as monotherapy, and the other study compared 
the combination to captopril and prazosin. For nitrates alone, 14 studies were identified, of 
which 13 studies included 1714 patients comparing nitrates to alternative interventions, and 
one study compared a high dose nitrate to a low dose nitrate [Table 1]. The mean age of 
participants was 62±8 years and 17% were women. The majority of studies assessed the 
effects in men with ADHF due predominantly to left ventricular systolic dysfunction (LVSD). 
The aetiology of heart failure was ischaemic heart disease (IHD) in about 76% of patients 
among all studies [Table 1].  
In a study by Nelson et al. (21), when isosorbide dinitrate and hydralazine combination (H-
ISDN) was used, by intravenous administration (the average dose of H was 11.6 mg and of 
ISDN was 13.4 mg over 90 minutes) in 18 men in sinus rhythm with ADHF secondary to IHD, 
it resulted in a composite haemodynamic profile, which was superior to either drug used 
alone. There was a significant reduction in left ventricular filling pressures, systolic and 
diastolic blood pressures and systemic vascular resistance, accompanied by a significant 
increase in stroke volume, cardiac output and heart rate, compared to either drug used 
alone. Given that combination therapy resulted in powerful preload and afterload 
reduction, it was concluded that combination therapy may be of greater benefit as long as 
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the fall in mean arterial pressure does not compromise peripheral perfusion, as it appears 
that the large fall in mean arterial blood pressure was not fully compensated by the reflex 
increase in heart rate and cardiac output. In another study by Adigun et al. (29), 17 Nigerian 
patients with hypertensive ADHF (35% were women and all patients were in sinus rhythm) 
were given H-ISDN combination therapy (intravenous H 30 mg and oral ISDN 30 mg), as 
compared to captopril 50 mg and prazosin 1 mg given orally in a single-blind parallel group 
fashion on a background therapy of standard treatments of acute pulmonary oedema 
including a furosemide diuretic. The neurohormonal inhibitors captopril and prazosin 
exerted the same haemodynamic effects of combination therapy (i.e. reduced left 
ventricular filling pressures, systolic and diastolic blood pressures and systemic vascular 
resistance) over 24 hours, yet without causing tachycardia, suggesting that there may be a 
favourable haemodynamic profile associated with these agents in ADHF. 
In comparison with furosemide, ISDN showed no effect on pulmonary artery pressures, 
suggesting no real major haemodynamic differences between the two agents when given 
over 90 minutes, mainly in men with ADHF secondary to IHD (17, 22). In a landmark study, 
Cotter et al. reported that high dose ISDN given as repeated intravenous boluses after low 
dose intravenous furosemide was beneficial in controlling severe pulmonary oedema in 104 
patients with a mean age of 74±9 years (48% were women), compared to low dose ISDN 
given after high dose intravenous furosemide (24). The high dose ISDN significantly 
decreased the need for mechanical ventilation and the frequency of myocardial infarction. 
In that study, all patients were in sinus rhythm and the aetiology of heart failure was IHD in 
64% of patients. The mean dose of ISDN administered during treatment was 11.4±6.8 mg in 
the high dose group and 1.4 ± 0.6 mg in the low dose group. The mean furosemide doses 
were 56±28 mg and 200±65 mg, respectively. Although the study by Cotter et al. has 
positively influenced clinical practice to date; it is debatable that the results are difficult to 
interpret because of nitrates were used in both arms of the study (9). 
The VMAC study compared nitroglycerine infusion, nesiritide infusion and placebo in 489 
patients with ADHF (26). Nitroglycerine and nesiritide significantly reduced symptoms of 
heart failure, but only nesiritide significantly reduced pulmonary artery pressures compared 
to placebo. In another study, Cohn et al. reported that short-term (48 hours) sodium 
nitroprusside infusion may cause a decrease in mortality if only used more than 9 hours 
after establishment of left ventricular failure following acute myocardial infarction (15). 
Interestingly, this study from 1982 is considered the only randomised study to show any 
reduction in mortality with nitrate use in the setting of heart failure. In comparison with 
hydralazine, ISDN reduced filling pressures, and improved symptoms of heart failure (16, 18, 






Organic nitrates have been commonly prescribed to patients with heart failure mainly for 
the relief of concomitant angina symptoms, with excellent clinical results. However, their 
long-term use has been partly limited by tolerance in those patients. For some time, it has 
been known that the early development of nitrate tolerance with frequent administration of 
oral preparations or continuous administration of intravenous preparations or long-acting 
topical preparations, leads to significant attenuation of the drug effects (30). The 
mechanisms underlying this phenomenon are still poorly understood. Since the increasing 
awareness of this problem, extensive research has been conducted to understand the 
underlying mechanisms in order to prevent nitrate tolerance. Consequently, few 
approaches have been introduced into clinical practice, including the application of a 
nitrate-free interval or the administration of concomitant drugs that have been suggested to 
reduce or prevent nitrate tolerance. Only a few randomised studies assessed nitrate 
tolerance with respect to the haemodynamic and anti-ischaemic effects in heart failure. 
Some of these studies reported conflicting results. There is some evidence to suggest that 
long-term oral administration of ISDN and isosorbide mononitrate (ISMN) is associated with 
sustained haemodynamic effects in patients with congestive heart failure (31, 32). N-
acetylcysteine was suggested to be associated with the potentiation of the haemodynamic 
effects of ISDN in patients with stable heart failure (33). The concomitant use of oral 
hydralazine with intravenous nitroglycerine was found to prevent the early development of 
nitrate tolerance (30). However, with respect to glyceryltrinitrate therapy (34, 35), or 
sodium nitroprusside (35), no benefit of adding hydralazine was observed. Wada et al. 
suggested that ACEI or angiotensin receptor blockers (ARB) may prevent the development 
of nitrate tolerance (36). Intravenous nicorandil remained haemodynamically effective 
during the first 24-hour infusion in patients with congestive heart failure (37, 38), partly due 
to its action as a potassium channel opener (37). It was suggested that this could represent 
a clinical advantage of nicorandil in the short-term treatment of patients with ADHF. 
However, more studies are needed to support this hypothesis (39).  
 
DISCUSSION 
The review including available randomised studies suggest that nitrates do not confer a 
mortality benefit in the management of ADHF. Current evidence suggests that nitrates may 
have some benefit, as an add-on therapy, to relieve symptoms of heart failure. The 
reduction in heart failure symptoms with nitrates may in part relate to reduction in left 
ventricular filling pressure, consistent with the lowering of pulmonary artery pressure seen 
with the same agents in the CHAMPION trial (10). The benefit was mostly observed in male 
patients predominantly in sinus rhythm, and having ADHF secondary to IHD [Table 1]. This is 
not surprising given the fact that in a recent UK survey, IHD was responsible for almost 50% 
of all cases hospitalised with a diagnosis of heart failure (1). There is insufficient data 
concerning the use of nitrates in female patients, patients with AHFS who have atrial 
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fibrillation, preserved left ventricular systolic function, or non-ischaemic aetiology of heart 
failure.  
AHFS is a very common presentation to general hospitals, with sizeable human and 
economic burden. Contemporary medical treatment with angiotensin converting enzyme 
inhibitors (ACEI), beta adrenoceptor antagonists (BB) and mineralocorticoid receptor 
antagonists (MRA), now approximately doubles life expectancy of patients with stable heart 
failure (40). However, mortality rates remain high, particularly in the first year after a 
hospitalisation for heart failure (1). Despite decades of progress, it is estimated that around 
800,000 people in the UK currently suffer from heart failure, with this being responsible for 
about 5% of all emergency hospital admissions (41). In the United States, there are around 
5.1 million people with heart failure, with many people hospitalised ADHF every year (42). 
According to the 2012/13 UK National Heart Failure Audit (41), most people admitted to 
hospital with a diagnosis of acute heart failure are aged over 75 years, with 66% aged 
between 75 years and 84 years and 30% are over 85 years. Men and women seem to be 
equally affected, but the majority of patients up to 85 years were men, and for those aged 
more than 85 years, most were women. Given the advancing age of patients in the recent 
years, it is possible that heart failure survival rate has improved as a result of more effective 
healthcare strategies, including the advances in management of coronary disease. 
Patients with AHFS are generally classified into two major categories; those who present 
with heart failure for the first time, and those who have an acute exacerbation of chronic 
heart failure. In fact, all physicians are trained to be familiar with the initial management of 
acute heart failure, which includes oxygen, morphine, diuretics and nitrates, as described in 
standard textbooks (43) and guidelines. Current guidelines from the European Society of 
Cardiology, American College of Cardiology and American Heart Association advocate the 
additional use of inotropic agents (e.g. dopamine, dobutamine and nor-adrenaline) only if 
previous treatments provide inadequate improvement. This is mainly due to the long-
standing concern that these agents may increase mortality. It is surprising that, to date, 
there are only a few randomised studies to validate the optimal management of AHFS. 
Indeed, it may well be that developing AHFS management has been neglected, with no new 
agents approved for use, for almost a quarter-century.  
The haemodynamic hallmark of AHFS includes an elevated left ventricular filling pressure, 
raised vascular resistance and a normal or diminished cardiac output. The main goal of 
initial management used to be haemodynamic stabilization and symptom improvement. 
Contemporary management continues to focus on improving haemodynamics and relief of 
symptoms by relieving congestion, which may be considered an appropriate strategy to a 
certain extent (44). Conventional treatment with acute diuretic therapy (i.e. intravenous 
furosemide; the most commonly used loop diuretic in clinical practice) may have the 
disadvantage of causing a large fall in cardiac output leading temporarily to acute pump 
dysfunction in occasional patients with left ventricular failure (45, 46). This has led to the 
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search for newer agents with effects not only to improve haemodynamics and symptoms, 
but also to improve clinical outcomes, with reduction in mortality and hospitalisation. 
Vasodilator therapy with nitrates, particularly with isosorbide dinitrate, nitroglycerine and 
nesiritide, has provided some promising results in clinical practice, as suggested by large 
observational studies (47, 48). A post-hoc analysis of the ALARM-HF registry suggested 
lower in-hospital mortality of AHFS patients receiving a vasodilator in combination with a 
diuretic than a diuretic alone (49). However, loop diuretics have remained the mainstay of 
AHFS management. This is mainly because the decision to use vasodilators is sometimes 
complex. Vasodilators should probably be avoided in patients presenting with ADHF 
associated with hypotension or severe mitral or aortic stenosis, for fear of increased 
mortality (40). 
Available studies are have been limited by the small number of patients and the different 
dosing regimens and clinical outcomes. None of the included studies have reported any 
cost-effectiveness analysis. Further high-quality studies are needed to improve our 
understanding in the growing acute heart failure patient population. There is little evidence 
to support the use of nitrates in AHFS, other than for possible heamodynamic benefit, and 
certainly no hard data to support a reduction in mortality or morbidity with these agents. 
Further large, randomised trials are needed to evaluate the safety and efficacy of these 
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